Cargando…

Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics

AIMS: Application of advanced molecular pathology in rare tumours is hindered by low sample numbers, access to specialised expertise/technologies and tissue/assay QC and rapid reporting requirements. We assessed the feasibility of co‐ordinated real‐time centralised pathology review (CPR), encompassi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crosier, Stephen, Hicks, Debbie, Schwalbe, Edward C., Williamson, Daniel, Leigh Nicholson, Sarah, Smith, Amanda, Lindsey, Janet C., Michalski, Antony, Pizer, Barry, Bailey, Simon, Bown, Nick, Cuthbert, Gavin, Wharton, Stephen B., Jacques, Thomas S., Joshi, Abhijit, Clifford, Steven C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600954/ https://www.ncbi.nlm.nih.gov/pubmed/33826763 http://dx.doi.org/10.1111/nan.12716

Ejemplares similares

Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study
por: Hill, Rebecca M, et al.
Publicado: (2020)

MBRS-44. TIME, PATTERN AND OUTCOME OF MEDULLOBLASTOMA RELAPSE ARE ASSOCIATED WITH TUMOUR BIOLOGY AT DIAGNOSIS AND UPFRONT THERAPY: A COHORT STUDY
por: Hill, Rebecca, et al.
Publicado: (2020)

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study
por: Schwalbe, Edward C, et al.
Publicado: (2017)

MBRS-60. THE ACTIONABLE GENOMIC LANDSCAPE OF RELAPSED MEDULLOBLASTOMA IS DEFINED BY MAINTENANCE AND ACQUISITION OF DRIVER EVENTS
por: Richardson, Stacey, et al.
Publicado: (2020)

Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development
por: Williamson, Daniel, et al.
Publicado: (2022)

Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse
por: Richardson, Stacey, et al.
Publicado: (2021)

Single-cell DNA sequencing identifies risk-associated clonal complexity and evolutionary trajectories in childhood medulloblastoma development
por: Danilenko, Marina, et al.
Publicado: (2022)

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease
por: Hill, Rebecca M., et al.
Publicado: (2015)

MEDB-36. Clinical and molecular heterogeneity withinMYC andMYCN amplified medulloblastoma
por: Schwalbe, Edward, et al.
Publicado: (2022)

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION
por: Goddard, Jack, et al.
Publicado: (2021)

MBRS-59. SINGLE-CELL WHOLE-GENOME SEQUENCING DISSECTS INTRA-TUMOURAL GENOMIC HETEROGENEITY AND CLONAL EVOLUTION IN CHILDHOOD MEDULLOBLASTOMA
por: Danilenko, Marina, et al.
Publicado: (2020)

MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES
por: Bennett, Christopher, et al.
Publicado: (2020)

MEDB-71. Molecular characterisation of group 4 medulloblastoma improves risk-stratification and its biological understanding
por: Goddard, Jack, et al.
Publicado: (2022)

OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING
por: Thompson, Dean, et al.
Publicado: (2021)

PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing
por: Thompson, Dean, et al.
Publicado: (2022)

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification
por: Goddard, Jack, et al.
Publicado: (2023)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
por: Clifford, Steven C., et al.
Publicado: (2015)

MEDB-65. Molecular subclassification of a national cohort of pediatric medulloblastoma based on methylation profile
por: Alaña, Lide, et al.
Publicado: (2022)

MEDB-31. THE CLINICAL SIGNIFICANCE OF EXTENT OF RESECTION IN MEDULLOBLASTOMA
por: Keeling, Claire, et al.
Publicado: (2022)

The Centralisation of Energy
por: Wooton, Edwin
Publicado: (1880)

Inconsistent centralised versus non-centralised ischaemic stroke aetiology
por: Suo, Yue, et al.
Publicado: (2020)

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
por: Sharma, Tanvi, et al.
Publicado: (2019)

Deriving a continuum score for group 3 and 4 medulloblastoma tumor samples analyzed via RNA-sequencing or DNA methylation microarray
por: Hacking, James P.R., et al.
Publicado: (2023)

Centralised treatment, entry to trials and survival.
por: Stiller, C. A.
Publicado: (1994)

Hospital Centralisation at Aberdeen
Publicado: (1887)

A centralised approach
por: Mannan, K. A. A.
Publicado: (2020)

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance
por: Lindsey, Janet C., et al.
Publicado: (2014)

What drives centralisation in cancer care?
por: Kilsdonk, Melvin J., et al.
Publicado: (2018)

Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial
por: Goschzik, Tobias, et al.
Publicado: (2018)

Centralisation of ROOT Help Systems
por: Khairallah, Elie
Publicado: (2018)

MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA
por: Llargués-Sistac, Gemma, et al.
Publicado: (2020)

Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity
por: Grabovska, Yura, et al.
Publicado: (2020)

Hospital Libraries: A Scheme for Centralisation
Publicado: (1919)

MEDB-43. Development of a bioinformatics pipeline for identification of differential DNA methylation events associated with medulloblastoma relapse
por: Kui, Christopher, et al.
Publicado: (2022)

MEDB-79. MYC-driven upregulation of thede novo serine and glycine pathway is a novel therapeutic target for Group 3 MYC-amplified Medulloblastoma
por: Adiamah, Magretta, et al.
Publicado: (2022)

Impact of emergency care centralisation on mortality and efficiency: a retrospective service evaluation
por: Price, Christopher, et al.
Publicado: (2020)

Variation in quality of acute stroke care by day and time of admission: prospective cohort study of weekday and weekend centralised hyperacute stroke unit care and non-centralised services
por: Melnychuk, Mariya, et al.
Publicado: (2019)

Anomaly Detection for the Centralised Elasticsearch Service at CERN
por: Andersson, Jennifer R, et al.
Publicado: (2021)

Centralisation versus Decentralisation: How to Fight Tuberculosis
Publicado: (1917)

Anomaly Detection for the Centralised Elasticsearch Service at CERN
por: Andersson, Jennifer R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f0rk7moisjn5a5j9vsfd5h8joj